MARKET

BOLT

BOLT

Bolt Biotherapeutics, Inc.
NASDAQ
5.42
+0.11
+2.07%
After Hours: 5.38 -0.04 -0.74% 16:04 12/05 EST
OPEN
5.11
PREV CLOSE
5.31
HIGH
5.45
LOW
5.11
VOLUME
5.85K
TURNOVER
--
52 WEEK HIGH
13.00
52 WEEK LOW
4.410
MARKET CAP
10.40M
P/E (TTM)
-0.2434
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BOLT last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at BOLT last week (1117-1121)?
Weekly Report · 11/24 09:30
Weekly Report: what happened at BOLT last week (1110-1114)?
Weekly Report · 11/17 09:31
Buy Rating for Bolt Biotherapeutics: Innovative Approach and Strong Financials Drive Positive Outlook
TipRanks · 11/14 15:55
Bolt Biotherapeutics GAAP EPS of -$3.72 beats by $1.72, revenue of $2.17M beats by $1.32M
Seeking Alpha · 11/13 17:48
Bolt Reports Q3 2025 Financial Results And Highlights Progress Across Oncology Pipeline
NASDAQ · 11/13 08:33
Bolt Biotherapeutics Reports Improved Financial Performance
TipRanks · 11/13 04:21
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 11/12 22:25
More
About BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Webull offers Bolt Biotherapeutics Inc stock information, including NASDAQ: BOLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BOLT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BOLT stock methods without spending real money on the virtual paper trading platform.